Trajan Group Holdings Ltd · ASX:TRJ
Trajan — Shareholder Meeting (November 2021)
18 slides from Trajan's shareholder meeting presentation, Nov 24, 2021
Slide 1: 2021 Annual General Meeting
Sci ence that benefits people For personal use only 2021 Annual General Meeting Stephen Tomisich, CEO and Managing Director, 24 November 2021
Slide 2: About Trajan
About Trajan Sci ence that benefits people For personal use only Global developer and manufacturer of analytical and life sciences products and devices. Founded to have a positive impact on human wellbeing through scientific measurement. • Products and solutions used in the analysis of biological, f
Slide 3: About Trajan
About Trajan Sci ence that benefits people For personal use only Now over 500 people, six manufacturing sites across the US, Europe, Australia, and Malaysia.
Slide 4: Trajan in FY21
Trajan in FY21 Sci ence that benefits people For personal use only $76.6M 16%* $9.95M Organic Proforma Total Revenue EBITDA Revenue Growth * Constant currency basis • FY21 results demonstrated the consistent performance of the core business. • Revenue, margins and profitability in line with prospect
Slide 5: Trajan FY22 Update
Trajan FY22 Update Sci ence that benefits people For personal use only • In the FY21 report we reinforced confidence in achieving the pre-IPO FY22 revenue forecast of $82.56M and $10.68M EBITDA. • In FY21 we reported organic revenue growth of 16% on a constant currency basis. Achievement of the FY22
Slide 6: Accelerating progress towards our vision
Accelerating progress towards our vision Sci ence that benefits people A future of personalized, preventative, data based healthcare. For personal use only
Slide 7: Target investment areas
ASX:TRJ Target investment areas Sci ence that benefits people For personal use only • Activity underway to leverage IPO funds: • Progressing acquisition targets. • Delivering margin gains through operational infrastructure and improvements. Neptune • Accelerating commercialization of new technologie
Slide 8: M&A
M&A Sci ence that benefits people For personal use only • Building on the “My Health Test” acquisition completed in May. • Build the laboratory capability for translation. • Investment into Humankind Ventures, “FORTH”. • Develop expertise in the consumer portal. • Acquisition of Axel Semrau. • Build
Slide 9: Why My Health Test?
Why My Health Test? Sci ence that benefits people For personal use only Trajan now has its own laboratory operations • Personal, preventative, measurement requires remote sampling. Prevention is about monitoring not testing. • Adoption of remote micro-sampling formats requires easy to adopt, product
Slide 10: Why Forth?
Why Forth? Sci ence that benefits people For personal use only Analytical information empowering the consumer • Realisation of personalised health care requires consumer engagement with actionable information. • Technology interfaces to the non-technical (“direct to consumer”) is new to Trajan. • Fo
Slide 11: Why Axel Semrau?
Why Axel Semrau? Sci ence that benefits people For personal use only Building a global laboratory automation capability and business • Axel Semrau is a “sibling” of Trajan’s existing Automation business; the two companies have worked closely together. • Trajan’s presence is weighted to North America
Slide 12: Operations, Neptune and beyond
Operations, Neptune and beyond Sci ence that benefits people For personal use only Targeting annual gross margin gains of $2.7M on current volumes. Build new technical capabilities Project Neptune Continue expanding global Centres of Excellence Production Automation Deliver CI initiatives with minor
Slide 13: Technology Commercialisation
Technology Commercialisation Sci ence that benefits people For personal use only • Key roles being recruited to drive; • hemaPEN®: “Healthy heart” related biomarker monitoring, COVID-19 Antibody response and Therapeutic Drug Monitoring. • Hummingbird: Decentralized measurements in the Pharmaceutical
Slide 14: Reflections as a Founder and CEO
ASX:TRJ as a Founder and CEO Sci ence that benefits people For personal use only • Transition to a public company has gone very well. • Constructive Board. • Staff well engaged. • Governance practices working well. • COVID Impact. • Operational and market risk diminished. • Supply chain responsivene
Slide 15: What our customers are saying?
What our customers are saying? Sci ence that benefits people For personal use only Pathology customers in Australia: “Your team is so responsive…” “…it’s about having suppliers like Trajan that we know we can rely on.” “In times of COVID, Trajan’s service levels have stood out even more.” Monash Uni
Slide 16: Looking forward
Looking forward Sci ence that benefits people For personal use only • With partial contribution from acquisitions we now expect full year FY22 revenues to approach $100M, with an underlying annual run rate well above that level as we head into FY23. • As we consider full year revenue and profitabili
Slide 17: Disclaimer
Disclaimer Sci ence that benefits people For personal use only The material in this presentation is general background information about Trajan Group Holdings Limited ( Trajan) and is current at the date of the presentation, [25 August 2021]. The information in the presentation is provided for infor
Slide 18: Q&A
Q&A Sci ence that benefits people For personal use only
Trajan Group Holdings — Shareholder Meeting (November 2021) on 6ix